Evaluating NLR and CRP as Cost-Effective Prognostic Markers in STEMI
Neutrophil-to-Lymphocyte Ratio AND C-REATIVE PROTEIN Useful as Cost-Effective Preliminary Prognostic Markers in ST-Elevation Myocardial Infarction
This study is testing if two simple blood tests can help doctors predict how well patients with a heart attack will do, especially in places where healthcare is limited.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Trial ID | NCT06491667 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the utility of the neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein (CRP) as cost-effective inflammatory biomarkers for predicting outcomes in patients with ST-segment elevation myocardial infarction (STEMI). It focuses on patients aged 18 and older who present with increased serum cardiac biomarkers or specific ECG changes indicative of STEMI. The study seeks to address the need for affordable prognostic tools in regions with limited healthcare resources, particularly in developing countries. By evaluating these markers, the study hopes to improve risk stratification and management of STEMI patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with STEMI based on cardiac biomarkers or ECG findings.
Not a fit: Patients with non-ST elevation myocardial infarction (NSTEMI), unstable angina, or those with conditions affecting NLR or CRP will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a low-cost method for early risk assessment in STEMI patients, potentially improving patient outcomes.
How similar studies have performed: While the use of NLR and CRP as inflammatory markers has been explored, this specific approach in the context of STEMI in resource-limited settings is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with age ≥18 years of either sex, with either increase in serum cardiac biomarkers or ECG are STEMI. Exclusion Criteria: * Patients presenting with NSTEMI and unstable angina * Patients with any of these associated conditions that can affect NLR or CRP including * Inflammatory conditions such as collagen-vascular disorders * Acute or chronic infectious diseases. * Auto-immune and neoplastic diseases. * Chronic hepatic diseases. * Renal failure. * Thyroid disorders. * Previous valvular heart disease.
Where this trial is running
Sohag
- Sohag university hospital — Sohag, Egypt (Recruiting)
Study contacts
- Principal investigator: Magdy M Amin, Professor — Sohag University
- Study coordinator: Albair Y Kaiser, Resident
- Email: Alberyouseef@med.edu.eg
- Phone: 01010095136
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.